These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7977011)

  • 21. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.
    Kreisberg RA; Oberman A
    J Clin Endocrinol Metab; 2002 Feb; 87(2):423-37. PubMed ID: 11836262
    [No Abstract]   [Full Text] [Related]  

  • 22. Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials.
    Waters D; Lespérance J
    Am J Med; 1991 Jul; 91(1B):10S-17S. PubMed ID: 1867231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy?
    Montague T; Tsuyuki R; Burton J; Williams R; Dzavik V; Teo K
    Chest; 1994 Mar; 105(3):718-26. PubMed ID: 8131532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiographic trials of lipid-lowering therapy: end of an era?
    Thompson GR
    Br Heart J; 1995 Oct; 74(4):343-7. PubMed ID: 7488443
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic control of hyperlipidemia in the prevention of coronary atherosclerosis: a review of results from recent clinical trials.
    Bilheimer DW
    Am J Cardiol; 1988 Nov; 62(15):1J-9J. PubMed ID: 3055918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of lipid-lowering therapy.
    Stein JH; McBride P
    J Am Board Fam Pract; 1998; 11(5):423-4. PubMed ID: 9796776
    [No Abstract]   [Full Text] [Related]  

  • 27. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-lowering for lower limb atherosclerosis.
    Leng GC; Price JF; Jepson RG
    Cochrane Database Syst Rev; 2000; (2):CD000123. PubMed ID: 10796489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients.
    Teo KK; Corsi DJ; Tam JW; Dumesnil JG; Chan KL
    Can J Cardiol; 2011; 27(6):800-8. PubMed ID: 21742465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation of clinical benefit to metabolic effects in lipid-lowering therapy.
    Herd JA
    Am J Cardiol; 1998 Sep; 82(6A):22M-25M. PubMed ID: 9766344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid lowering drugs and coronary heart disease.
    Scott PJ
    Drugs; 1975; 10(3):218-25. PubMed ID: 1104340
    [No Abstract]   [Full Text] [Related]  

  • 36. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
    Oparil S
    Hypertension; 2003 May; 41(5):1006-9. PubMed ID: 12695423
    [No Abstract]   [Full Text] [Related]  

  • 38. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression and regression of the atherosclerotic plaque.
    de Feyter PJ; Vos J; Deckers JW
    Eur Heart J; 1995 Aug; 16 Suppl I():26-30. PubMed ID: 8829954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the benefits of lipid-lowering therapy.
    Gotto AM
    Am J Cardiol; 1998 Sep; 82(6A):2M-4M. PubMed ID: 9766341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.